Utility of measuring plasma N‐terminal pro‐brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats

Wess, Gerhard; Daisenberger, Patricia; Mahling, Monia; Hirschberger, Johannes; Hartmann, Katrin

doi:10.1111/j.1939-165x.2011.00305.x

Cited by 52 publications

(82 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second‐generation quantitative plate ELISA used in our study had sensitivity and specificity (84.6 and 100%) similar to previously reported values (sensitivity, 71–92%; specificity, 78–100%) for both the first‐ and second‐generation quantitative assays . The POC ELISA had a lower sensitivity (65.4%) and higher specificity (100%) than previously reported (83.4 and 82.6%) .…”

Section: Discussionsupporting

confidence: 87%

“…The study found that the percentage of cats with positive POC ELISA results increased as the severity of cardiac disease increased (normal [11.3%], equivocal [12.5%], mild [24%], moderate [83.9%], and severe [83.3%]) . Several other studies have evaluated the ability of the quantitative NT‐proBNP to distinguish among different grades or severity of cardiomyopathy . In these studies, cats with severe cardiomyopathy had significantly higher NT‐proBNP concentrations than did those with mild cardiomyopathy, and NT‐proBNP was found to be less accurate at identifying mild grades of disease, with more false‐negative results than false‐positive results .…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have investigated the ability of this assay to distinguish echocardiographically normal cats from those with subclinical cardiomyopathy. These studies have shown that NT‐proBNP concentration can distinguish healthy cats from those with subclinical disease (sensitivity, 70.9–92.4%; specificity, 93.9–100%) . Plasma NT‐proBNP concentrations >100 pmol/L indicate that morphologic cardiac changes may be present and further cardiac evaluation is warranted.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Investigation of an N‐Terminal Prohormone of Brain Natriuretic Peptide Point‐of‐Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease

Harris

Beatty

Estrada

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundN‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) concentrations may be increased in cats with various cardiac disorders. The point‐of‐care (POC) ELISA assay uses the same biologic reagents as the quantitative NT‐proBNP ELISA. Previous studies have evaluated the sensitivity and specificity of the POC ELISA in cats with cardiac disease.ObjectivesTo prospectively evaluate the diagnostic utility of the POC ELISA in a select population of cats.AnimalsThirty‐eight client‐owned cats presented to the University of Florida Cardiology Service for cardiac evaluation. Fifteen apparently healthy cats recruited as part of another study.MethodsPhysical examination and echocardiography were performed in all cats. The POC ELISA was assessed visually as either positive or negative by a reader blinded to the echocardiographic findings, and results were analyzed relative to quantitative assay results.ResultsTwenty‐six cats were diagnosed with underlying cardiac disease, and 27 cats were considered free of cardiac disease. Cats with cardiac disease included: 21 with hypertrophic cardiomyopathy, 2 with unclassified cardiomyopathy, 2 with restrictive cardiomyopathy, and 1 with 3rd degree atrioventricular (AV) block. The POC ELISA differentiated cats with cardiac disease with a sensitivity of 65.4% and specificity of 100%.Conclusions and Clinical ImportanceThe POC NT‐proBNP ELISA performed moderately well in a selected population of cats. A negative test result cannot exclude the presence of underlying cardiac disease, and a positive test result indicates that cardiac disease likely is present, but further diagnostic investigation would be indicated for a definitive diagnosis.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Investigation of an N‐Terminal Prohormone of Brain Natriuretic Peptide Point‐of‐Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease

Harris

Beatty

Estrada

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Specific assays have therefore been developed to measure these NP in the different species [43,44]. Also, in dogs and cats, NPs have been found to be useful to distinguish CHF from respiratory disease [43,[46][47][48][49] and increased plasma concentrations of NPs have been identified in dogs with DCM [50-54] and cats with HCM [48,49,[55][56][57]. Also, in dogs and cats, NPs have been found to be useful to distinguish CHF from respiratory disease [43,[46][47][48][49] and increased plasma concentrations of NPs have been identified in dogs with DCM [50-54] and cats with HCM [48,49,[55][56][57].…”

Section: Natriuretic Peptides As Cardiac Biomarkersmentioning

confidence: 99%

Cardiovascular endocrinology in naturally occurring canine and feline models

Häggström¹,

Ljungvall²,

Höglund

2014

Cardiovascular Endocrinology

View full text Add to dashboard Cite

Rodents are frequently used to study aspects of cardiovascular endocrinology. The present review focuses on opportunities offered by naturally occurring heart disease in dogs and cats, that is larger animal models. In particular, the benefits of using these species include the possibility of studying the same types of naturally occurring diseases as those occurring in humans, and carrying out studies in genetically similar individuals (i.e. breeds) sharing the same environment as humans. Recent findings in neuroendocrine hormones, that is natriuretic peptides, components of the renin-angiotensinaldosterone system, and endothelin-1, in dogs and cats are reviewed in this article. As in humans, all these hormones have been evaluated as cardiovascular biomarkers in dogs and cats, and natriuretic peptides have shown promise in the diagnosis, staging and prognostication of heart disease. However, components of the renin-angiotensin-aldosterone system and endothelin-1 appear to be more useful as functional biomarkers for monitoring compensatory responses to naturally occurring heart diseases and their treatments.Percent of angiotensin II (ANG II) formation from angiotensinconverting enzyme (ACE) and chymase in hearts from multiple species showing that more than 90% of ANG II formation was from chymase in dogs and humans, whereas more than 90% was from ACE in rat, mouse and rabbit. The green bar indicates chymase and the yellow bar represents ACE. From Dell'Italia [8] with permission from publisher.Neuroendocrines in canine and feline models Hä ggströ m et al. 33

show abstract

“…10 NT-proBNP is released in proportion to the amount of stretch and stress on the myocardium, and the concentration is often increased in cats with heart disease relative to cats without. 8,12 The first-generation feline NT-proBNP immunoassay a provided linear quantitative measurement of NT-proBNP in ethylenediamine tetra-acetic acid (EDTA) plasma samples in a range of 24-1,500 pmol/L, with intra-and interassay precision (%CV) of <15% at points across that range. 8 Sample handling limitations were placed on the assay due to the labile nature of NT-proBNP at room temperature.…”

Section: Introductionmentioning

confidence: 99%

Analytical validation of an immunoassay for the quantification of N-terminal pro–B-type natriuretic peptide in feline blood

et al. 2015

View full text Add to dashboard Cite

The measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker for heart stress detectable in blood, has been shown to have clinical utility in cats with heart disease. A second-generation feline enzyme-linked immunosorbent assay (Cardiopet® proBNP, IDEXX Laboratories Inc., Westbrook, Maine) was developed to measure NT-proBNP in routine feline plasma or serum samples with improved analyte stability. Results of the analytical validation for the second-generation assay are presented. Analytic sensitivity was 10 pmol/l. Accuracy of 103.5% was determined via serial dilutions of 6 plasma samples. Coefficients of variation for intra-assay, interassay, and total precision were in the ranges of 1.6-6.3%, 4.3-8.8%, and 10.1-15.1%, respectively. Repeatability across 2 lots for both serum and plasma had an average coefficient of determination (r(2)) of 0.99 and slope of 1.11. Stability of the analyte was found to be high. In serum samples held at 4°C for 24-72 hr, the mean percent recovery from time zero was ≥99%. In serum samples held at 25°C for 24 hr, the mean percent recovery from time zero was 91.9%, and for 48 hr, 85.6%. A method comparison of the first- and second-generation assays with a clinically characterized population of cats revealed no difference in the tests' ability to differentiate levels of NT-proBNP between normal cats and cats with occult cardiomyopathy (P < 0.001). Results from our study validate that the second-generation feline Cardiopet proBNP assay can measure NT-proBNP in routine feline plasma and serum samples with accuracy and precision.

show abstract

Utility of measuring plasma N‐terminal pro‐brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats

Abstract: NT-proBNP with a cut-off value of >100 pmol/L was useful in detecting even mild HCM. Cats with increased NT-proBNP concentrations should be examined by echocardiography.

Cited by 52 publications

References 44 publications

Investigation of an N‐Terminal Prohormone of Brain Natriuretic Peptide Point‐of‐Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease

Investigation of an N‐Terminal Prohormone of Brain Natriuretic Peptide Point‐of‐Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease

Cardiovascular endocrinology in naturally occurring canine and feline models

Analytical validation of an immunoassay for the quantification of N-terminal pro–B-type natriuretic peptide in feline blood

Contact Info

Product

Resources

About